Prevalence of cognitive decline and associated factors in elderly type 2 diabetic patients at inclusion in the GERODIAB cohort

Cardiovascular Complications Over 5 Years and Their Association With Survival in the GERODIAB Cohort of Elderly French Patients With Type 2 Diabetes

“…Patients were 77 years old (median) (IQR 73-80), including 36.7% of patients between the ages of 75 and 80 years and 28.5% of patients aged 80 years and older. They had diabetes for 16 years (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25). Their BMI was 29 kg/m 2 (26-33), the systolic blood pressure was 140 mmHg (128-150), and the diastolic blood pressure was 73 mmHg (67-80); 90% of the patients were treated with cardiovascular drugs, including diuretics 53%, sartans 40%, ACE inhibitors 39%, b-blockers 38%, calcium channel blockers 37%, nitrates 7%, anticoagulants 12%, and platelet aggregation inhibitors 56%.…”

“…A limitation of our study is the percentage of patients (13.3%) lost to follow-up. This is not an excessive number compared with previous studies involving younger patients, considering that ambulatory followup may be difficult in elderly patients owing to their decreased autonomy or cognitive alterations, or when living far from diabetes centers (21)(22)(23). However, the patients lost to follow-up did not differ significantly from the other patients, except for sex and a mildly impaired nutritional status (Supplementary Table 1).…”

“…seldom studied in this age range. This is likely to be related to the recent increase in life expectancy in the general population and to the difficulty managing studies in elderly patients, especially interventional studies (21)(22)(23). The different increases in the frequencies of complications have been observed in patients taking several treatments, especially cardiovascular drugs (Supplementary Table 1).…”

Management of Diabetes in Elderly

“…[18]. Ces troubles cognitifs sont fréquemment sous-estimés ainsi qu'en témoigne les résultats de l'étude Gérodiab, dans laquelle une discordance importante était notée entre l'estimation grossière faite le praticien et l'évaluation objective réalisée par le MMSE [19]. Ce fait est important à noter car il conditionne la compréhension des recommandations concernant l'alimentation et le traitement notamment par insuline.…”

Medical treatments of elderly, French patients with type 2 diabetes: results at inclusion in the GERODIAB Cohort

“…It is therefore difficult to know whether their medication treatment follows the recommendations and whether it is suitable to their clinical situation. The GERODIAB study is the first French, multicentre, prospective, observational, 5‐year follow‐up study designed to analyse the relation between glycaemic control and morbidity–mortality in type 2 diabetic patients aged 70 years and older . We report here on the results of their diabetic and geriatric situations at the study inclusion according to the treatment used.…”